Literature DB >> 7506096

A mutation in CFTR produces different phenotypes depending on chromosomal background.

S Kiesewetter1, M Macek, C Davis, S M Curristin, C S Chu, C Graham, A E Shrimpton, S M Cashman, L C Tsui, J Mickle.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene but the association between mutation (genotype) and disease presentation (phenotype) is not straightforward. We have been investigating whether variants in the CFTR gene that alter splicing efficiency of exon 9 can affect the phenotype produced by a mutation. A missense mutation, R117H, which has been observed in three phenotypes, was found to occur on two chromosome backgrounds with intron 8 variants that have profoundly different effects upon splicing efficiency. A close association is shown between chromosome background of the R117H mutation and phenotype. These findings demonstrate that the genetic context in which a mutation occurs can play a significant role in determining the type of illness produced.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506096     DOI: 10.1038/ng1193-274

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  88 in total

1.  Genetic counselling after carrier detection by newborn screening when one parent carries DeltaF508 and the other R117H.

Authors:  L Curnow; R Savarirayan; J Massie
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

2.  Long-range (17.7 kb) allele-specific polymerase chain reaction method for direct haplotyping of R117H and IVS-8 mutations of the cystic fibrosis transmembrane regulator gene.

Authors:  Genevieve Pont-Kingdon; Mohamed Jama; Christine Miller; Alison Millson; Elaine Lyon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

3.  CFTR mutation analysis and haplotype associations in CF patients.

Authors:  S K Cordovado; M Hendrix; C N Greene; S Mochal; M C Earley; P M Farrell; M Kharrazi; W H Hannon; P W Mueller
Journal:  Mol Genet Metab       Date:  2011-10-26       Impact factor: 4.797

4.  Microsphere bead arrays and sequence validation of 5/7/9T genotypes for multiplex screening of cystic fibrosis polymorphisms.

Authors:  Andrew G Hadd; Walairat Laosinchai-Wolf; Chris R Novak; Marty R Badgett; Lesley A Isgur; Marianna Goldrick; Cindy R Walkerpeach
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

5.  Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis.

Authors:  P W Miller; A Hamosh; M Macek; P A Greenberger; J MacLean; S M Walden; R G Slavin; G R Cutting
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

Review 6.  Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling.

Authors:  D A S de Souza; F R Faucz; L Pereira-Ferrari; V S Sotomaior; S Raskin
Journal:  Andrology       Date:  2017-12-07       Impact factor: 3.842

7.  A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype.

Authors:  Jérôme Clain; Jacqueline Lehmann-Che; Emmanuelle Girodon; Joanna Lipecka; Aleksander Edelman; Michel Goossens; Pascale Fanen
Journal:  Hum Genet       Date:  2005-03-03       Impact factor: 4.132

Review 8.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

9.  Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships.

Authors:  Kristina V Krasnov; Maria Tzetis; Jie Cheng; William B Guggino; Garry R Cutting
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

Review 10.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.